LifeStent 5F Vascular Stent System
Bard Peripheral Vascular, Inc. · Decision date May 15, 2026
What did the FDA approve?
FDA records P070014/S068 as a supplement to PMA P070014, with the supplement type “Real-Time Process”. The recorded decision is approval, dated May 15, 2026.
FDA approval order statement
Approval for enhancing the flexibility of the inner catheter component
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- May 15, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P070014/S068
- Regulatory pathway
- PMA supplement
- Applicant
- Bard Peripheral Vascular, Inc.
- Product code
- NIP
- Decision code
- APPR
- Decision date
- May 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.
- Applicant
- Bard Peripheral Vascular, Inc.
- Product code
- NIP
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P070014/S066 · Related supplement
LifeStent Vascular Stent Systems
P070014/S068 received
Application receipt date recorded by FDA.
P070014/S067 · Related supplement
LIFESTENT FLEXSTAR & FLEXSTAR XL VASCULAR STENT SYSTEM
P070014/S068 · FDA decision
Real-Time Process
P070014/S069 · Related supplement
LifeStent 5F Vascular Stent Systems
Timeline entries are records held by MedtechLedger for P070014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P070014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LifeStent Vascular Stent SystemsP070014/S066 | Bard Peripheral Vascular, Inc. | PMA supplement | Dec 16, 2025 | FDA |
| Bard Peripheral Vascular, Inc. | PMA supplement | Mar 10, 2026 | FDA | |
LifeStent 5F Vascular Stent SystemsP070014/S069 | Bard Peripheral Vascular, Inc. | PMA supplement | Jun 10, 2026 | FDA |
Explore the linked device profile
Other records with product code NIP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Supera Peripheral Stent SystemP120020/S037 | Abbott Vascular (Idef Technologies Inc) | PMA supplement | Nov 6, 2026 | FDA |
| Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA | |
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bard Peripheral Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1415 W. 3rd St., Tempe, AZ, 85281
Sources and methodology
- Original FDA record: P070014/S068
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





